Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8235952 | International Journal of Radiation Oncology*Biology*Physics | 2009 | 7 Pages |
Abstract
Twice-weekly gemcitabine with concurrent RT is well tolerated and provides rates of survival and bladder preservation that are comparable to the existing literature. All locoregional failures were successfully salvaged by either radical cystectomy or intravesical therapy. Given the high proportion of late local failures, we recommend long-term monitoring when using this regimen. Future studies comparing the safety and efficacy of gemcitabine- vs. platinum-based bladder preservation protocols are pending.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Kevin S. M.D., Daniel E. M.D., David C. M.D., James E. M.D., Cheryl T. M.D., Howard M. M.D.,